MB-CART2019.1 Clinical Trials
3 recruitingBiologic
Phase 22Not Applicable1
Showing 1–3 of 3 trials
Recruiting
Phase 2
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Miltenyi Biomedicine GmbH213 enrolled52 locationsNCT04844866
Recruiting
Phase 2
DALY II Japan/MB-CART2019.1 for DLBCL
DLBCL - Diffuse Large B Cell Lymphoma
Miltenyi Biomedicine GmbH31 enrolled5 locationsNCT07288879
Recruiting
Not Applicable
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Melanoma Stage IVPediatric ALLMelanoma Stage III+4 more
Miltenyi Biomedicine GmbH40 enrolled7 locationsNCT06508775